|
|||||
|
|
Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial |
|
| Authors: | Jonathan C. Nelson Peter D. Beitsch Frank A. Vicini Coral A. Quiet Delia Garcia Howard C. Snider Mark A. Gittleman Victor J. Zannis Pat W. Whitworth Richard E. Fine Angela J. Keleher Henry M. Kuerer |
| Affiliation: | a Department of Surgical Oncology, The University of Texas M. D. Anderson, Cancer Center, 1515 Holcombe Blvd., Unit 444, Houston, TX 77030, USA b Department of Surgery, Dallas Breast Center, Dallas, TX, USA c Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA d Foundation for Cancer Research and Education, Arizona Oncology Services, Scottsdale, AZ, USA e Department of Radiation Oncology, St. Louis Cancer & Breast Center, St. Louis, MO, USA f Department of Surgery, Alabama Breast Center, Montgomery, AL, USA g Department of Surgery, Sacred Heart Hospital, Allentown, PA, USA h Department of Surgery, Breast Care Center of the Southwest, Phoenix, AZ, USA i Nashville Breast Center, Nashville, TN, USA j Advanced Breast Care, Marietta, GA, USA k Department of Surgery, Vassar Brothers Medical Center, Poughkeepsie, NY, USA |
| Abstract: | BackgroundWe present a 4-year update on the efficacy, cosmetic results, and complications of MammoSite breast brachytherapy in patients enrolled in the American Society of Breast Surgeons registry trial.MethodsA total of 1,449 breasts in 1,440 patients with early stage breast cancer undergoing breast-conserving therapy were treated with adjuvant, accelerated partial breast irradiation (APBI) (34 Gy in 3.4-Gy fractions) delivered with the MammoSite device. The median follow-up period for the entire group was 36.1 months.ResultsThe 3-year actuarial rate of ipsilateral breast tumor recurrence was 2.15%. The 3-year actuarial rate of axillary recurrence was .36%. Complication rates were as follows: infection, 9.5%; seroma, 26.8% (symptomatic seroma, 12.7%); and fat necrosis, 2.0%. The percentages of breasts with good or excellent cosmetic results were as follows: 12 months, 95%; 24 months, 94%; 36 months, 94%; and 48 months, 91%.ConclusionsLocoregional control, complications, and cosmetic outcomes from MammoSite APBI at the 4-year update are acceptable and similar to results seen with other forms of APBI. |
| Keywords: | Breast-conserving therapy Brachytherapy Radiation Partial breast irradiation MammoSite |
| 本文献已被 ScienceDirect 等数据库收录！ | |